ArticleEntropy (Basel, Switzerland)2024
Optimizing Prognostic Predictions in Liver Cancer with Machine Learning and Survival Analysis.
Article in Entropy (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The translational paradox of AI in hepatocellular carcinoma: from algorithmic over-engineering to real-world clinical utility.Frontiers in oncology · 2026Review
- Machine learning-driven comprehensive profiling of tumor heterogeneity and sialylation in hepatocellular carcinoma.NPJ precision oncology · 2025Article
- Integrating radiomics and machine learning for the diagnosis and prognosis of hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- Comprehensive exploration of signal sequence receptor subunit 1 (SSR1) as a diagnostic and prognostic biomarker in liver hepatocellular carcinoma.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study harnesses RNA sequencing data from the Cancer Genome Atlas to unearth pivotal genetic markers linked to the progression of liver hepatocellular carcinoma (LIHC), a major contributor to cancer-related deaths worldwide, characterized by a dire prognosis and limited treatment avenues. We employ advanced feature selection techniques, including sure independence screening (SIS) combined with the least absolute shrinkage and selection operator (Lasso), smoothly clipped absolute deviation (SCAD), information gain (IG), and permutation variable importance (VIMP) methods, to effectively navigate the challenges posed by ultra-high-dimensional data. Through these methods, we identify critical genes like MED8 as significant markers for LIHC. These markers are further analyzed using advanced survival analysis models, including the Cox proportional hazards model, survival tree, and random survival forests. Our findings reveal that SIS-Lasso demonstrates strong predictive accuracy, particularly in combination with the Cox proportional hazards model. However, when coupled with the random survival forests method, the SIS-VIMP approach achieves the highest overall performance. This comprehensive approach not only enhances the prediction of LIHC outcomes but also provides valuable insights into the genetic mechanisms underlying the disease, thereby paving the way for personalized treatment strategies and advancing the field of cancer genomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.